Charles Schwab Investment Management Inc Xencor Inc Transaction History

Charles Schwab Investment Management Inc

  • $515 Billion
  • Q3 2024

A detailed history of Charles Schwab Investment Management Inc transactions in Xencor Inc stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 626,988 shares of XNCR stock, worth $15.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
626,988
Previous 586,200 6.96%
Holding current value
$15.8 Million
Previous $11.1 Million 13.63%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024
BUY
$15.7 - $21.65 $640,371 - $883,060
40,788 Added 6.96%
626,988 $12.6 Million
Q2 2024

Aug 12, 2024
BUY
$18.21 - $24.5 $605,992 - $815,311
33,278 Added 6.02%
586,200 $11.1 Million
Q1 2024

May 08, 2024
BUY
$18.65 - $26.52 $600,977 - $854,580
32,224 Added 6.19%
552,922 $12.2 Million
Q4 2023

Feb 06, 2024
BUY
$16.53 - $21.42 $533,109 - $690,816
32,251 Added 6.6%
520,698 $11.1 Million
Q3 2023

Nov 08, 2023
BUY
$20.08 - $25.39 $207,747 - $262,684
10,346 Added 2.16%
488,447 $9.84 Million
Q2 2023

Aug 09, 2023
BUY
$24.77 - $29.9 $91,227 - $110,121
3,683 Added 0.78%
478,101 $11.9 Million
Q1 2023

May 11, 2023
SELL
$25.95 - $36.95 $102,995 - $146,654
-3,969 Reduced 0.83%
474,418 $13.2 Million
Q4 2022

Feb 13, 2023
BUY
$24.79 - $30.86 $314,411 - $391,397
12,683 Added 2.72%
478,387 $12.5 Million
Q3 2022

Nov 14, 2022
BUY
$24.62 - $32.44 $304,524 - $401,250
12,369 Added 2.73%
465,704 $12.1 Million
Q2 2022

Aug 15, 2022
SELL
$19.74 - $29.01 $37,841 - $55,612
-1,917 Reduced 0.42%
453,335 $12.4 Million
Q1 2022

May 13, 2022
BUY
$26.68 - $41.63 $327,817 - $511,507
12,287 Added 2.77%
455,252 $12.1 Million
Q4 2021

Feb 11, 2022
BUY
$33.67 - $43.44 $261,885 - $337,876
7,778 Added 1.79%
442,965 $17.8 Million
Q3 2021

Nov 16, 2021
BUY
$30.65 - $35.68 $1.11 Million - $1.3 Million
36,335 Added 9.11%
435,187 $14.2 Million
Q2 2021

Aug 16, 2021
BUY
$34.33 - $44.68 $326,237 - $424,594
9,503 Added 2.44%
398,852 $13.8 Million
Q1 2021

May 17, 2021
BUY
$40.81 - $53.88 $582,644 - $769,244
14,277 Added 3.81%
389,349 $16.8 Million
Q4 2020

Feb 16, 2021
SELL
$36.63 - $47.63 $279,633 - $363,607
-7,634 Reduced 1.99%
375,072 $16.4 Million
Q3 2020

Nov 13, 2020
BUY
$30.09 - $43.02 $351,722 - $502,860
11,689 Added 3.15%
382,706 $14.8 Million
Q2 2020

Aug 14, 2020
BUY
$27.76 - $33.42 $1.55 Million - $1.87 Million
55,872 Added 17.73%
371,017 $12 Million
Q1 2020

May 15, 2020
BUY
$20.69 - $37.79 $363,750 - $664,385
17,581 Added 5.91%
315,145 $9.42 Million
Q4 2019

Feb 07, 2020
BUY
$32.75 - $41.43 $211,368 - $267,389
6,454 Added 2.22%
297,564 $10.2 Million
Q3 2019

Nov 08, 2019
BUY
$33.73 - $46.27 $407,323 - $558,756
12,076 Added 4.33%
291,110 $9.82 Million
Q2 2019

Aug 09, 2019
BUY
$29.6 - $40.93 $238,132 - $329,281
8,045 Added 2.97%
279,034 $11.4 Million
Q1 2019

May 14, 2019
BUY
$27.85 - $38.09 $333,643 - $456,318
11,980 Added 4.63%
270,989 $8.42 Million
Q4 2018

Feb 14, 2019
BUY
$32.39 - $42.05 $50,107 - $65,051
1,547 Added 0.6%
259,009 $9.37 Million
Q3 2018

Nov 13, 2018
BUY
$35.69 - $47.65 $462,934 - $618,068
12,971 Added 5.31%
257,462 $10 Million
Q2 2018

Aug 08, 2018
BUY
$28.41 - $42.41 $1.18 Million - $1.76 Million
41,617 Added 20.51%
244,491 $9.05 Million
Q1 2018

May 07, 2018
BUY
$21.18 - $33.78 $30,562 - $48,744
1,443 Added 0.72%
202,874 $6.08 Million
Q4 2017

Jan 17, 2018
BUY
$19.29 - $24.83 $269,481 - $346,875
13,970 Added 7.45%
201,431 $4.42 Million
Q3 2017

Nov 13, 2017
BUY
$19.61 - $23.35 $3.68 Million - $4.38 Million
187,461
187,461 $4.3 Million

Others Institutions Holding XNCR

# of Institutions
216
Shares Held
71.8M
Call Options Held
2.5K
Put Options Held
7.9K
View Full List

About Xencor Inc

XNCR Quotes by TradingView
  • Ticker XNCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,698,100
  • Market Cap $1.51B
  • Description
  • Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal ...
More about XNCR
Track This Portfolio

Track Charles Schwab Investment Management Inc Portfolio

Follow Charles Schwab Investment Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email